Page last updated: 2024-12-06

4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone: structure; from tobacco smoke [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID47289
CHEMBL ID2311069
CHEBI ID32692
SCHEMBL ID454516
MeSH IDM0066689

Synonyms (71)

Synonym
4-(n-nitroso-n-methylamino)-1-(3-pyridyl)-1-butanone
4-(methylnitrosamino)-1-(3-pyridyl)-1-(butanone)
4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-one
nnk (carcinogen)
64091-91-4
4-(n-nitrosomethylamino)-1-(3-pyridyl)butan-1-one
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone
CHEBI:32692 ,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
NNK ,
4-(n-nitrosomethylamino)-1-(3-pyridyl)-1-butanone
1-butanone, 4-(methylnitrosoamino)-1-(3-pyridinyl)-
4-[methyl(nitroso)amino]-1-pyridin-3-ylbutan-1-one
inchi=1/c10h13n3o2/c1-13(12-15)7-3-5-10(14)9-4-2-6-11-8-9/h2,4,6,8h,3,5,7h2,1h
brn 3548355
4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone
ccris 1150
4-(methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone
4-methylnitrosoamino-1-(3-pyridinyl)-1-butanone
4-(n-methyl-n-nitrosoamino)-4-(3-pyridyl)-1-butanone
4-(nitrosoamino-n-methyl)-1-(3-pyridyl)-1-butanone
ketone, 3-pyridyl 3-(n-methyl-n-nitrosamino)propyl
n-methyl-n-nitroso-4-oxo-4-(3-pyridyl)butyl amine
NCGC00163358-01
ozone/nnk
4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone
nnk cpd
n-methyl-n-(4-oxo-4-pyridin-3-ylbutyl)nitrous amide
64091-50-5
1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-
FT-0672061
FT-0672062
4-(nitrosomethylamino)-1-(3-pyridyl)-1-butanone
7s395edo61 ,
unii-7s395edo61
hsdb 7771
FT-0616837
1-butanone,4-(methylnitrosoamino)-1-(3-pyridinyl)-
CHEMBL2311069
SCHEMBL454516
methylnitrosoamino-1-(3-pyridinyl)-1-butanone, 4-
nnk (carcinogen) [hsdb]
4-(n-nitrosomethylamino)-1-(3-pyridyl)-1-butanone [iarc]
4-(n-nitrosomethylamino)-1-(3-pyridinyl)-1-butanone
FLAQQSHRLBFIEZ-UHFFFAOYSA-N
1-butanone, 4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)
4-(1-methyl-2-oxohydrazino)-1-(3-pyridinyl)-1-butanone #
tox21_303771
dtxsid3020881 ,
dtxcid70881
NCGC00357285-01
cas-64091-91-4
AKOS028109857
4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone, analytical standard
A50811
n-nitrosonornicotine-ketone
n-methyl-n-(4-oxo-4-(pyridin-3-yl)butyl)nitrous amide ,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (nnk)
Q6138931
mfcd00274580
BCP32075
nicotine-derived nitrosamine ketone
SY062201
n-methyl-n-[4-oxo-4-(pyridin-3-yl)butyl]nitrous amide
MS-23132
HY-126477
CS-0104774
4-(n-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (iarc)
4-methylnitrosamino-1,3-pyridyl-1-butanone
4-(methyl(nitroso)amino)-1-(pyridin-3-yl)butan-1-one
4-n-nitrosomethylamino-1-3-pyridyl-1-butanone

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" At high concentrations (100-200 micrograms/ml), NNK was significantly toxic to RTE cells."( Cytotoxicity, genotoxicity and transforming activity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rat tracheal epithelial cells.
Cunningham, ML; Gray, TE; Nettesheim, P; Zhu, SY, 1991
)
0.28
" These results suggest that the toxic effects of NNK and NDMA initiate a regenerative process that occurs faster in rat than in hamster liver."( DNA single-strand breaks and toxicity induced by 4-(methyl-nitrosamino)-1-(3- pyridyl)-1-butanone or N-nitrosodimethylamine in hamster and rat liver.
Castonguay, A; Jorquera, R; Schuller, HM, 1994
)
0.29
" The cancer initiating/promoting nature of cigarette smoke can be attributed to its various constituents including nicotine, which is the major psychoactive component, and several other toxic constituents, such as nitrosamines, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and polycyclic aromatic hydrocarbons."( Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.
Batra, SK; Kaur, S; Kumar, S; Momi, N; Ponnusamy, MP; Wittel, UA, 2012
)
0.38
"The tobacco-specific nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a carcinogenic and ubiquitous environmental pollutant for which toxic activity has been thoroughly investigated in murine models and human tissues."( Toxicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in early development: A wide-scope metabolomics assay in zebrafish embryos.
Casado, M; Merino, C; Piña, B; Ramírez, N; Vinaixa, M, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The formation and biological half-life of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the major metabolite of NNK, was also studied in these animal species."( Pharmacokinetics of N'-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in laboratory animals.
Adams, JD; Carey, KD; Hoffmann, D; Lavoie, EJ; Marshall, MV; O'Mara-Adams, KJ, 1985
)
0.27
"Methods were developed to determine the biological half-life of N'-nitrosonornicotine (NNN) and 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) in Syrian golden hamsters and Fischer rats."( Pharmacokinetics of tobacco-specific N-nitrosamines.
Adams, JD; Hoffmann, D; Lavoie, EJ; O'Donnell, M, 1984
)
0.27
" Pharmacokinetic parameters were consistent with those observed in previous studies of nitrosamines, and varied predictably with body weight of five species."( Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites.
Anderson, LM; Burak, ES; Carmella, SG; Gombar, CT; Hecht, SS; Jones, AB; Reid-Quinn, CA; Rice, JM; Southers, JL; Trushin, N, 1993
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the toxic and carcinogenic potential of ozone alone or in combination with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and/or dibutyl phthalate (DBP)."( Toxicity and carcinogenicity of ozone in combination with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone and dibutyl phthalate in B6C3F1 mice for 16 and 32 weeks.
Cho, MY; Kim, MY, 2009
)
0.82
" Oviductal carcinomas were observed in female mice exposed to ozone or DBP alone for 16 weeks and ozone in combination with NNK and DBP for 32 weeks."( Toxicity and carcinogenicity of ozone in combination with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone and dibutyl phthalate in B6C3F1 mice for 16 and 32 weeks.
Cho, MY; Kim, MY, 2009
)
0.6

Bioavailability

ExcerptReferenceRelevance
" This decrease in lung DNA methylation appears to be due to the decreased bioavailability of NNK and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in the lungs of I3C-treated mice which, in turn, may be a result of increased metabolic alpha-hydroxylation of NNK by the liver."( Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on the metabolism and disposition of NNK in A/J mice.
Amin, SG; Chung, FL; LaGreca, SD; Morse, MA, 1990
)
0.28
"The main reasons for the failure of most chemopreventive agents during clinical trials are poor in vivo bioavailability and dose-limiting side effects."( Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice.
Kassie, F; Melkamu, T; Qian, X; Song, JM; Upadhyaya, P, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" For both isothiocyanates, there were no statistically significant differences between dosing frequencies in inhibitory effects on tumor multiplicities and tumor incidences."( Effect of frequency of isothiocyanate administration on inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary adenoma formation in A/J mice.
Amin, SG; Chung, FL; Eklind, KI; Morse, MA, 1992
)
0.28
" The inhibitory effects of green tea infusion were also observed in a similar experiment using a higher dosage of NDEA (20 mg/kg)."( Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea.
Conney, AH; Hong, JY; Huang, MT; Reuhl, KR; Wang, ZY; Yang, CS, 1992
)
0.28
" The studies described in this paper illustrate the utility of performing dose-response experiments and the quantitation of DNA methylation and repair in not only target tissues but also target cell types."( Role of DNA methylation in the activation of proto-oncogenes and the induction of pulmonary neoplasia by nitrosamines.
Anderson, MW; Belinsky, SA; Devereux, TR,
)
0.13
" The effects of I3C on NNK-induced DNA methylation in the lungs and livers of A/J mice were assessed using the same dosing regimen as in the bioassay."( Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on the metabolism and disposition of NNK in A/J mice.
Amin, SG; Chung, FL; LaGreca, SD; Morse, MA, 1990
)
0.28
"The relationship between the formation of O6-methylguanine (O6MG) and the induction of lung, liver, and nasal tumors in the Fisher 344 rat by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was examined in a dose-response study."( Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Anderson, MW; Belinsky, SA; Foley, JF; Maronpot, RR; White, CM, 1990
)
0.28
" In contrast, the dose-response curve for methylation by NDMA appeared opposite of that for NNK with alkylation efficiency increasing as a function of dose."( Factors regulating activation and DNA alkylation by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone and nitrosodimethylamine in rat lung and isolated lung cells, and the relationship to carcinogenicity.
Anderson, MW; Belinsky, SA; Devereux, TR, 1988
)
0.53
" The dose-response to NNK was nonlinear; the ratio of O6-meG to dose, an index of alkylation efficiency, increased dramatically as the dose of carcinogen decreased."( Molecular dosimetry of O6-methylguanine formation and cell toxicity in lung and nasal mucosa by 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone.
Anderson, MW; Belinsky, SA; Swenberg, JA, 1987
)
0.27
" These mice, together with female A/J mice, were treated at 6-8 weeks of age with NNK or dosed with PEITC prior to administration of NNK."( K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate.
Anderson, MW; Crist, KA; Kelloff, GJ; Lubet, RA; Matzinger, SA; Pereira, MA; Steele, VE; Stoner, GD; You, M, 1995
)
0.29
" When isolated rat livers were perfused with 150 microM NNK, equal to a dosage which is sufficient to induce liver tumors in rat, glucuronidation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was increased when compared to the concentration of 35 nM NNK."( Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in isolated rat lung and liver.
Foth, H; Hirsch-Ernst, KI; Richter, E; Schrader, E, 1998
)
0.3
" NNK-derived radioactivity was still detectable in urine 10 days after dosing (total excretion, 92."( Metabolism and disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in rhesus monkeys.
A-Rahim, YI; Hargaden, MB; Meger, M; Oehlmann, C; Richter, E; Vesell, ES; Zwickenpflug, W, 1999
)
0.3
"Dietary myo-inositol is an effective inhibitor of lung tumor induction in mice, but no dose-response studies have been reported."( Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo.
Hecht, SS; Kenney, PM; Upadhyaya, P; Wang, M, 2001
)
0.31
" Three experiments were performed: (i) a dose-response study with vinyl carbamate-induced tumors; (ii) a limited treatment study also with vinyl carbamate and (iii) prevention of NNK-induced tumors."( Prevention of mouse lung tumors by targretin.
Alyaqoub, FS; Gunning, WT; Kramer, PM; Liu, Y; Lubet, RA; Nines, R; Pereira, MA; Steele, VE, 2006
)
0.33
" When NNK treatments were combined, the dose-response curve became bell-shaped where the MF at the highest radiation dose decreased substantially."( Combined genotoxic effects of radiation and a tobacco-specific nitrosamine in the lung of gpt delta transgenic mice.
Hayata, I; Ikeda, M; Masumura, K; Nenoi, M; Nohmi, T; Sakamoto, Y; Sakuma, K; Wang, B, 2007
)
0.34
" We substituted dimethyl sulfate (DMS) to create alkylating damage in pCMVluc plasmid DNA and established the damage-repair dose-response curves in both normal and nucleotide excision repair-deficient lymphoblastoid cell lines and in phytohemagglutinin (PHA)-stimulated primary lymphocytes."( A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma.
Guo, Z; Qiao, Y; Shi, Q; Spitz, MR; Wang, L; Wei, Q, 2007
)
0.34
" Microarray analysis revealed that, independent of the dose of NNK, expression of 30 genes was significantly altered; 22 of these genes showed a dose-response pattern."( Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
El-Bayoumy, K; Freeman, WM; Prokopczyk, B; Sinha, I; Trushin, N, 2009
)
0.35
" The approach using Bayesian methods better accounts for the uncertainty inherent in the values generated using input assumptions and provides for a more robust probabilistic dose-response assessment."( Bayesian derivation of an oral cancer slope factor distribution for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
Kathman, S; Naufal, Z; Wilson, C, 2009
)
0.35
" The discrepancy between cotinine levels in relation to disease risk comparing active versus passive smoking suggests a nonlinear tobacco smoke dose-response and/or that cotinine is not providing an accurate measure of exposure to the toxic constituents of secondhand tobacco smoke."( Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers.
Benowitz, N; Eisner, MD; Goniewicz, ML; Havel, C; Jacob, P; Koszowski, B; Lazcano-Ponce, E; Sobczak, A; Zielinska-Danch, W, 2010
)
0.36
" The association between the NNAL-Gluc/free NNAL ratio and UC risk was significant in a dose-response manner."( Low ratio of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol-glucuronides (NNAL-Gluc)/free NNAL increases urothelial carcinoma risk.
Chung, CJ; Hsueh, YM; Lee, HL; Lin, P; Pu, YS; Shiue, HS; Su, CT; Yang, HY, 2011
)
0.37
" Based on dose-response of γH2AX and Hill model, the ability to induce DSBs was evaluated: NNN-acetate > B[a]P > NNK-acetate > tar > nicotine."( Genotoxicity analysis of five particle matter toxicants from cigarette smoke based on γH2AX assay combined with Hill/Two-component model.
Chen, H; Hou, H; Hu, Q; Liu, Y; Wang, A; Zhang, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
nitrosamineN-Nitroso amines, compounds of the structure R2NNO. Compounds RNHNO are not ordinarily isolable, but they, too, are nitrosamines. The name is a contraction of N-nitrosoamine and, as such, does not require the N locant.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency76.95880.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1653806Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653796Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653791Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653801Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (956)

TimeframeStudies, This Drug (%)All Drugs %
pre-199078 (8.16)18.7374
1990's282 (29.50)18.2507
2000's294 (30.75)29.6817
2010's275 (28.77)24.3611
2020's27 (2.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (1.50%)5.53%
Reviews44 (4.41%)6.00%
Case Studies1 (0.10%)4.05%
Observational0 (0.00%)0.25%
Other938 (93.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]